The University of Southampton
University of Southampton Institutional Repository

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Anti-IgE therapy with omalizumab reduces serum levels of free IgE and downregulates expression of IgE receptors (Fc?RI) on mast cells and basophils. In the airways of patients with mild allergic asthma, omalizumab reduces Fc?RI+ and IgE+ cells and causes a profound reduction in tissue eosinophilia, together with reductions in submucosal T-cell and B-cell numbers. In patients with seasonal allergic rhinitis, omalizumab inhibits the allergen-induced seasonal increases in circulating and tissue eosinophils. Omalizumab decreases Fc?RI expression on circulating dendritic cells, which might lead to a reduction in allergen presentation, TH2 cell activation, and proliferation. As a systemic anti-IgE agent, omalizumab has demonstrated clinical efficacy in patients with moderate and severe allergic asthma and in those with seasonal and perennial allergic rhinitis, as well as in patients with concomitant allergic asthma and allergic rhinitis. The anti-inflammatory effects of omalizumab at different sites of allergic inflammation and the clinical benefits of anti-IgE therapy in patients with allergic asthma and allergic rhinitis emphasize the fundamental importance of IgE in allergic inflammation.
Abbreviations used: BHR, Bronchial hyperresponsiveness; EAR, Early asthmatic response; ICS, Inhaled corticosteroid; LAR, Late asthmatic response; pDC, Precursor dendritic cell; SAR, Seasonal allergic rhinitis
IgE, omalizumab, anti-inflammatory, Fc?RI, Fc?RII, T cell, B cell, allergic inflammation
0091-6749
459-465
Holgate, S.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Casale, T.
368e395b-87fb-4c02-becd-2e9423fd5a21
Wenzel, S.
08a5766a-f896-44ac-9a0f-880fda76f9c1
Bousquet, J.
fda25127-be6f-45cd-a455-883cc90d8e0e
Deniz, Y.
e85c1a2a-3a78-4a4f-9327-83e116a5df24
Reisner, C.
424cee9d-ae5c-49db-b092-2e35d65f6a88
Holgate, S.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Casale, T.
368e395b-87fb-4c02-becd-2e9423fd5a21
Wenzel, S.
08a5766a-f896-44ac-9a0f-880fda76f9c1
Bousquet, J.
fda25127-be6f-45cd-a455-883cc90d8e0e
Deniz, Y.
e85c1a2a-3a78-4a4f-9327-83e116a5df24
Reisner, C.
424cee9d-ae5c-49db-b092-2e35d65f6a88

Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y. and Reisner, C. (2005) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. Journal of Allergy and Clinical Immunology, 115 (3), 459-465. (doi:10.1016/j.jaci.2004.11.053).

Record type: Article

Abstract

Anti-IgE therapy with omalizumab reduces serum levels of free IgE and downregulates expression of IgE receptors (Fc?RI) on mast cells and basophils. In the airways of patients with mild allergic asthma, omalizumab reduces Fc?RI+ and IgE+ cells and causes a profound reduction in tissue eosinophilia, together with reductions in submucosal T-cell and B-cell numbers. In patients with seasonal allergic rhinitis, omalizumab inhibits the allergen-induced seasonal increases in circulating and tissue eosinophils. Omalizumab decreases Fc?RI expression on circulating dendritic cells, which might lead to a reduction in allergen presentation, TH2 cell activation, and proliferation. As a systemic anti-IgE agent, omalizumab has demonstrated clinical efficacy in patients with moderate and severe allergic asthma and in those with seasonal and perennial allergic rhinitis, as well as in patients with concomitant allergic asthma and allergic rhinitis. The anti-inflammatory effects of omalizumab at different sites of allergic inflammation and the clinical benefits of anti-IgE therapy in patients with allergic asthma and allergic rhinitis emphasize the fundamental importance of IgE in allergic inflammation.
Abbreviations used: BHR, Bronchial hyperresponsiveness; EAR, Early asthmatic response; ICS, Inhaled corticosteroid; LAR, Late asthmatic response; pDC, Precursor dendritic cell; SAR, Seasonal allergic rhinitis

This record has no associated files available for download.

More information

Published date: 2005
Keywords: IgE, omalizumab, anti-inflammatory, Fc?RI, Fc?RII, T cell, B cell, allergic inflammation

Identifiers

Local EPrints ID: 27098
URI: http://eprints.soton.ac.uk/id/eprint/27098
ISSN: 0091-6749
PURE UUID: 97a75c68-c37b-4a74-9580-1654bead306d

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 15 Mar 2024 07:15

Export record

Altmetrics

Contributors

Author: S. Holgate
Author: T. Casale
Author: S. Wenzel
Author: J. Bousquet
Author: Y. Deniz
Author: C. Reisner

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×